1. Home
  2. FIS vs INSM Comparison

FIS vs INSM Comparison

Compare FIS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidelity National Information Services Inc.

FIS

Fidelity National Information Services Inc.

HOLD

Current Price

$46.99

Market Cap

34.0B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$106.84

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIS
INSM
Founded
1968
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.0B
30.1B
IPO Year
2001
2000

Fundamental Metrics

Financial Performance
Metric
FIS
INSM
Price
$46.99
$106.84
Analyst Decision
Buy
Strong Buy
Analyst Count
14
24
Target Price
$72.23
$201.17
AVG Volume (30 Days)
5.0M
2.0M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
3.81%
N/A
EPS Growth
N/A
N/A
EPS
0.73
N/A
Revenue
$10,677,000,000.00
N/A
Revenue This Year
$30.41
$182.31
Revenue Next Year
$4.76
$65.19
P/E Ratio
$64.29
N/A
Revenue Growth
5.43
N/A
52 Week Low
$43.30
$64.85
52 Week High
$82.74
$212.75

Technical Indicators

Market Signals
Indicator
FIS
INSM
Relative Strength Index (RSI) 49.15 22.41
Support Level $46.16 $101.55
Resistance Level $51.67 $166.81
Average True Range (ATR) 1.26 6.15
MACD 0.11 -2.15
Stochastic Oscillator 51.08 5.08

Price Performance

Historical Comparison
FIS
INSM

About FIS Fidelity National Information Services Inc.

Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: